Fulcrum and Slate Merge to Advance Next-Generation Migraine Treatments
Fulcrum and Slate merge to form Slate Medicines, advancing SLTE-1009, a dual-target antibody for migraine prevention, with $245M in funding.
NOTRELOAD AI
Alibaba Sells Lingxi Games to Trustar Capital in Deal Worth Over $2 Billion
Alibaba is selling gaming unit Lingxi Games to Trustar Capital in a deal worth more than $2 billion to focus on AI and cloud computing.
Biotech Firm OmniAb Rises Sharply After Signing Global Deal with Eli Lilly
OmniAb signs a global license deal with Eli Lilly focused on ion channel drug discovery, with an upfront payment, milestones, and tiered royalties.
Piper Sandler Starts Coverage on SoFi: Overweight Rating + Strong Growth Outlook
The company keeps growing by offering loans, banking and investing in one app, encouraging customers to use more services over time.
argenx’s VYVGART Shows Clinically Meaningful Benefit in Phase 3 Myositis Study, Stock Jumps
argenx’s efgartigimod met primary endpoint in Phase 3 ALKIVIA trial for autoimmune myositis, showing 15.4-point TIS improvement at Week 52.
Sidus Space Strengthens Cash Position but Posts Lower Revenue and Higher Cash Burn in Q2 2026
Sidus Space reported Q2 2026 revenue of $583,000 (−54% YoY) due to contract timing, a $5.1M adjusted EBITDA loss, $166.5M cash, and key LizzieSat milestones.